- Home
- SSP vs NBTX Comparison
SSP vs NBTX Comparison
Compare SSP & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSP
- NBTX
- Stock Information
- Founded
- SSP 1878
- NBTX 2003
- Country
- SSP United States
- NBTX France
- Employees
- SSP N/A
- NBTX N/A
- Industry
- SSP Broadcasting
- NBTX Biotechnology: Pharmaceutical Preparations
- Sector
- SSP Industrials
- NBTX Health Care
- Exchange
- SSP Nasdaq
- NBTX Nasdaq
- Market Cap
- SSP 177.0M
- NBTX 201.9M
- IPO Year
- SSP 1988
- NBTX 2020
- Fundamental
- Price
- SSP $2.02
- NBTX $3.26
- Analyst Decision
- SSP Buy
- NBTX Strong Buy
- Analyst Count
- SSP 2
- NBTX 1
- Target Price
- SSP $5.75
- NBTX $12.00
- AVG Volume (30 Days)
- SSP 540.3K
- NBTX 64.6K
- Earning Date
- SSP 11-04-2024
- NBTX 12-31-2024
- Dividend Yield
- SSP N/A
- NBTX N/A
- EPS Growth
- SSP N/A
- NBTX N/A
- EPS
- SSP N/A
- NBTX N/A
- Revenue
- SSP $2,397,162,000.00
- NBTX $45,220,186.00
- Revenue This Year
- SSP $10.34
- NBTX N/A
- Revenue Next Year
- SSP N/A
- NBTX N/A
- P/E Ratio
- SSP N/A
- NBTX N/A
- Revenue Growth
- SSP 1.66
- NBTX 526.17
- 52 Week Low
- SSP $1.68
- NBTX $2.76
- 52 Week High
- SSP $9.35
- NBTX $8.96
- Technical
- Relative Strength Index (RSI)
- SSP 45.29
- NBTX 42.55
- Support Level
- SSP $1.90
- NBTX $3.18
- Resistance Level
- SSP $2.24
- NBTX $3.69
- Average True Range (ATR)
- SSP 0.17
- NBTX 0.27
- MACD
- SSP -0.01
- NBTX 0.07
- Stochastic Oscillator
- SSP 20.63
- NBTX 56.45
About SSP E.W. Scripps Company (The)
The E W Scripps Co is a media enterprise with interests in local and national media brands. It owns and operates a collection of daily and community newspapers in medium-sized cities in the southern and western portions of the United States. The company's operating segment includes Local Media, Scripps Networks, and Other. It generates maximum revenue from the Local Media segment. The Local Media segment includes local broadcast stations and their related digital operations.
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.